DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Yau T, Zagonel V, Santoro A. et al.
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
J Clin Oncol 2020;
38 (Suppl. 04) 478-478
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.